Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33170484,time to maximum pimasertib concentration,"The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules.",Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33170484/),h,1.5,271,DB00171,Adenosine triphosphate
,33170484,apparent terminal half-life,"The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules.",Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33170484/),h,5,272,DB00171,Adenosine triphosphate
,33990984,t1/2,"After intravenous infusion, RDV is rapidly metabolized (t1/2 = 1 h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and then it can be found in plasma in its nucleoside analogue form (GS-441524).",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,1,1908,DB00171,Adenosine triphosphate
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],<,1909,DB00171,Adenosine triphosphate
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1910,DB00171,Adenosine triphosphate
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1911,DB00171,Adenosine triphosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1912,DB00171,Adenosine triphosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],122.3,1913,DB00171,Adenosine triphosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2637.3,1914,DB00171,Adenosine triphosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1915,DB00171,Adenosine triphosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1916,DB00171,Adenosine triphosphate
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1917,DB00171,Adenosine triphosphate
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],3676.5,1918,DB00171,Adenosine triphosphate
>,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2610,1919,DB00171,Adenosine triphosphate
,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],140,1920,DB00171,Adenosine triphosphate
>,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],1560,1921,DB00171,Adenosine triphosphate
,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],2230,1922,DB00171,Adenosine triphosphate
,33990984,t1/2,The mean t1/2 value for GS-441524 was 26.3 h.,Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,26.3,1923,DB00171,Adenosine triphosphate
,17417072,concentration-to-dose ratio,"A post-hoc analysis revealed that FLV concentration-to-dose ratio was significantly higher in the TT genotype group as compared with the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.861 vs 0.434, P = 0.026).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.861,4380,DB00171,Adenosine triphosphate
,17417072,concentration-to-dose ratio,"A post-hoc analysis revealed that FLV concentration-to-dose ratio was significantly higher in the TT genotype group as compared with the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.861 vs 0.434, P = 0.026).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.434,4381,DB00171,Adenosine triphosphate
,17417072,concentration-to-dose ratio,"FLV concentration-to-dose ratio was significantly higher in the CT + TT genotype group than the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.618 vs 0.434, P = 0.031).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.618,4382,DB00171,Adenosine triphosphate
,17417072,concentration-to-dose ratio,"FLV concentration-to-dose ratio was significantly higher in the CT + TT genotype group than the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.618 vs 0.434, P = 0.031).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.434,4383,DB00171,Adenosine triphosphate
,9353401,terminal half-lives,The larger volume of distribution at steady state of the 8-substituted analogs resulted in terminal half-lives (ranging from 17 to 24 min) which were significantly longer than for CPA (7 min).,8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),min,17 to 24,9455,DB00171,Adenosine triphosphate
,9353401,terminal half-lives,The larger volume of distribution at steady state of the 8-substituted analogs resulted in terminal half-lives (ranging from 17 to 24 min) which were significantly longer than for CPA (7 min).,8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),min,7,9456,DB00171,Adenosine triphosphate
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,366,9457,DB00171,Adenosine triphosphate
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,210,9458,DB00171,Adenosine triphosphate
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,170,9459,DB00171,Adenosine triphosphate
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,175,9460,DB00171,Adenosine triphosphate
,1496913,initial half-life,"(ii) Release of cysteinyl leukotrienes into the blood circulation is followed by a rapid elimination with an initial half-life of 38 sec in rats and 4.0 min in man, as measured with the labeled, representative LTC4 catabolite, N-acetyl-LTE4.",Transport and in vivo elimination of cysteinyl leukotrienes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496913/),s,38,10404,DB00171,Adenosine triphosphate
,1496913,initial half-life,"(ii) Release of cysteinyl leukotrienes into the blood circulation is followed by a rapid elimination with an initial half-life of 38 sec in rats and 4.0 min in man, as measured with the labeled, representative LTC4 catabolite, N-acetyl-LTE4.",Transport and in vivo elimination of cysteinyl leukotrienes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496913/),min,4.0,10405,DB00171,Adenosine triphosphate
,21465812,t1/2beta,"Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1).",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,22.5-23.3,13888,DB00171,Adenosine triphosphate
,21465812,V(d),"Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1).",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),[l] / [kg],0.956 4-0.978 6,13889,DB00171,Adenosine triphosphate
,21465812,CL,"Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1).",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),[l] / [kg·min],0.029,13890,DB00171,Adenosine triphosphate
,21465812,t(max),"The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,20,13891,DB00171,Adenosine triphosphate
,21465812,t1/2kappa (m),"The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,40.6-42.7,13892,DB00171,Adenosine triphosphate
,21465812,f(m),"The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),%,60,13893,DB00171,Adenosine triphosphate
,21465812,t(max),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,65-95,13894,DB00171,Adenosine triphosphate
,21465812,t1/2kappa (m),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,56.0-57.7,13895,DB00171,Adenosine triphosphate
,21465812,bioavailability F(m),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),%,55,13896,DB00171,Adenosine triphosphate
,21465812,bioavailability F(m),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),%,62,13897,DB00171,Adenosine triphosphate
,21465812,t(max),"PCr i.v. administration resulted in significant elevation of ATP level in RBC but not in plasma, the related-ATP in RBC was characterized by t(max) 68-83 min, t1/2kappa 49-52 min.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,68-83,13898,DB00171,Adenosine triphosphate
,21465812,t1/2kappa,"PCr i.v. administration resulted in significant elevation of ATP level in RBC but not in plasma, the related-ATP in RBC was characterized by t(max) 68-83 min, t1/2kappa 49-52 min.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,49-52,13899,DB00171,Adenosine triphosphate
,21465812,t(max),"In RBC no exogenous PCr was found but Cr was detected following i.v. administration of PCr, with the t(max) 120 min and t1/2k (m) 70 min for Cr.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,120,13900,DB00171,Adenosine triphosphate
,21465812,t1/2k (m),"In RBC no exogenous PCr was found but Cr was detected following i.v. administration of PCr, with the t(max) 120 min and t1/2k (m) 70 min for Cr.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,70,13901,DB00171,Adenosine triphosphate
,22727067,relative bioavailability,The relative bioavailability of the test formulation was estimated to be 102.1% (13.5%).,"Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727067/),%,102.1,14459,DB00171,Adenosine triphosphate
,9651106,constant flow rate,The liver was perfused with a recirculating system at a constant flow rate of 20 ml/min.,The pharmacokinetic change of lidocaine by catecholamines using isolated perfused rat liver (IPRL). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9651106/),[ml] / [min],20,22690,DB00171,Adenosine triphosphate
,8540705,half-life,"IsoddA was inefficiently phosphorylated in CEM cells; however, the half-life of the triphosphate was 9.4 h, and IsoddATP was a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 16 nM.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),h,9.4,40839,DB00171,Adenosine triphosphate
,8540705,Ki,"IsoddA was inefficiently phosphorylated in CEM cells; however, the half-life of the triphosphate was 9.4 h, and IsoddATP was a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 16 nM.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),nM,16,40840,DB00171,Adenosine triphosphate
greater,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,100,40841,DB00171,Adenosine triphosphate
,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,12,40842,DB00171,Adenosine triphosphate
,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,11,40843,DB00171,Adenosine triphosphate
,9533533,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],47,43981,DB00171,Adenosine triphosphate
,9533533,AUC,"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],22,43982,DB00171,Adenosine triphosphate
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,15,43983,DB00171,Adenosine triphosphate
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,10,43984,DB00171,Adenosine triphosphate
,9533533,terminal t(1/2),The median terminal t(1/2) of CdA in plasma was 21 h.,Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,21,43985,DB00171,Adenosine triphosphate
,17112803,area under the curve from 36 to 48 hours,"The mean plasma methotrexate area under the curve from 36 to 48 hours after the start of the infusion was significantly 2-fold higher in female patients carrying at least 1 -24T allele as compared with all other patients (14.2+/-12.8 h.micromol/L versus 6.9+/-4.2 h.micromol/L, P<.001).",High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112803/),[h·μM] / [l],14.2,48756,DB00171,Adenosine triphosphate
,17112803,area under the curve from 36 to 48 hours,"The mean plasma methotrexate area under the curve from 36 to 48 hours after the start of the infusion was significantly 2-fold higher in female patients carrying at least 1 -24T allele as compared with all other patients (14.2+/-12.8 h.micromol/L versus 6.9+/-4.2 h.micromol/L, P<.001).",High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112803/),[h·μM] / [l],6.9,48757,DB00171,Adenosine triphosphate
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.26,49026,DB00171,Adenosine triphosphate
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.23,49027,DB00171,Adenosine triphosphate
,9145874,Ki,"The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),nM,21,49028,DB00171,Adenosine triphosphate
,9145874,IC50s,"1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines.","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,110,49029,DB00171,Adenosine triphosphate
,9145874,oral bioavailability,1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT.,"1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),%,105,49030,DB00171,Adenosine triphosphate
,19398602,terminal disposition half-life,The mean terminal disposition half-life was between 41 and 43 hours independently of dose.,"Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398602/),h,41 and 43,50276,DB00171,Adenosine triphosphate
,19398602,EC(50),"The effect of LXR-623 concentration on ABCA1 and ABCG1 expression was further characterized via a population pharmacokinetic-pharmacodynamic analysis, yielding EC(50) estimates of 526 ng/mL and 729 ng/mL, respectively.","Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398602/),[ng] / [ml],526,50277,DB00171,Adenosine triphosphate
,19398602,EC(50),"The effect of LXR-623 concentration on ABCA1 and ABCG1 expression was further characterized via a population pharmacokinetic-pharmacodynamic analysis, yielding EC(50) estimates of 526 ng/mL and 729 ng/mL, respectively.","Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398602/),[ng] / [ml],729,50278,DB00171,Adenosine triphosphate
,32052462,maximum concentration,Noncompartmental pharmacokinetic analysis resulted in (mean ± standard deviation) a maximum concentration of 8749 ± 2840 ng/mL and half-life of 2.1 ± 0.71 hr.,"Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052462/),[ng] / [ml],8749,53738,DB00171,Adenosine triphosphate
,32052462,half-life,Noncompartmental pharmacokinetic analysis resulted in (mean ± standard deviation) a maximum concentration of 8749 ± 2840 ng/mL and half-life of 2.1 ± 0.71 hr.,"Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052462/),h,2.1,53739,DB00171,Adenosine triphosphate
,21030608,influx rate constant k(in),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.65,56417,DB00171,Adenosine triphosphate
,21030608,influx rate constant k(in),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,2.12,56418,DB00171,Adenosine triphosphate
,21030608,elimination rate constant k(be),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.09,56419,DB00171,Adenosine triphosphate
,21030608,elimination rate constant k(be),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.17,56420,DB00171,Adenosine triphosphate
,21030608,efflux rate constant k(out),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.07,56421,DB00171,Adenosine triphosphate
,21030608,efflux rate constant k(out),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.02,56422,DB00171,Adenosine triphosphate
,21030608,extraction ratio,"Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 ± 0.05, n = 6) was significantly reduced compared with 0.93 ± 0.05 (n = 6) in normal rats.",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.86,56423,DB00171,Adenosine triphosphate
,21030608,extraction ratio,"Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 ± 0.05, n = 6) was significantly reduced compared with 0.93 ± 0.05 (n = 6) in normal rats.",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.93,56424,DB00171,Adenosine triphosphate
,12172971,peak,"In rats, [(3)H]8-Cl-AMP concentrations in PBMC were similar to those of the triphosphate metabolite which achieved a peak of 90 micro M 2 h after a bolus injection of 8-Cl-Ado (40 mg/kg).",Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172971/),μM,90,58665,DB00171,Adenosine triphosphate
,9598154,terminal half life (t1/2),The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,21.1,74598,DB00171,Adenosine triphosphate
,9598154,area under the curve (AUC),The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),μMh,1.2,74599,DB00171,Adenosine triphosphate
,9598154,t1/2,The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,14.6,74600,DB00171,Adenosine triphosphate
,9598154,t1/2,The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,9.7,74601,DB00171,Adenosine triphosphate
,9016325,oral bioavailability,"With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.",Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9016325/),%,47,77045,DB00171,Adenosine triphosphate
,9016325,plasma elimination half-life,"With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.",Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9016325/),h,3,77046,DB00171,Adenosine triphosphate
,20590629,pIC(50),"The pIC(50) estimates for these receptors ranged from 7.3 to 8.5, while concentrations 300-fold higher had little or no effect on other P2X channels or on an assortment of receptors, enzymes and transporter proteins.","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),,7.3 to 8.5,81834,DB00171,Adenosine triphosphate
,20590629,oral bioavailability (%F,"Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),,32.9,81835,DB00171,Adenosine triphosphate
,20590629,half-life (t(1/2),"Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),h,1.63,81836,DB00171,Adenosine triphosphate
,31871305,select,The selectivity for BTK over TEC found in these biochemical analyses was 1-1.5 for ibrutinib and 3.0-4.2 for acalabrutinib.,Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1-1.5,85108,DB00171,Adenosine triphosphate
,31871305,select,The selectivity for BTK over TEC found in these biochemical analyses was 1-1.5 for ibrutinib and 3.0-4.2 for acalabrutinib.,Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,3.0-4.2,85109,DB00171,Adenosine triphosphate
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,2.53,85110,DB00171,Adenosine triphosphate
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.05,85111,DB00171,Adenosine triphosphate
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.51,85112,DB00171,Adenosine triphosphate
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,0.97,85113,DB00171,Adenosine triphosphate
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.13,85114,DB00171,Adenosine triphosphate
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,2.56,85115,DB00171,Adenosine triphosphate
,31871305,selectivity,"The equivalent selectivity measured in samples from patients with CLL were 1.31 ± 0.27 and 1.09 ± 0.11 for ibrutinib and acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.31,85116,DB00171,Adenosine triphosphate
,31871305,selectivity,"The equivalent selectivity measured in samples from patients with CLL were 1.31 ± 0.27 and 1.09 ± 0.11 for ibrutinib and acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.09,85117,DB00171,Adenosine triphosphate
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],21.4,87213,DB00171,Adenosine triphosphate
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],88.1,87214,DB00171,Adenosine triphosphate
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],34.4,87215,DB00171,Adenosine triphosphate
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],41.4,87216,DB00171,Adenosine triphosphate
,8593479,Km,"The degradation of Ap4A in rat plasma was very rapid and could be explained by a Michaelis-Menten equation: Km and Vmax values were 1.69 micrograms/ml and 4.32 micrograms/min/ml, respectively.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),[μg] / [ml],1.69,90734,DB00171,Adenosine triphosphate
,8593479,Vmax,"The degradation of Ap4A in rat plasma was very rapid and could be explained by a Michaelis-Menten equation: Km and Vmax values were 1.69 micrograms/ml and 4.32 micrograms/min/ml, respectively.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),[μg] / [min·ml],4.32,90735,DB00171,Adenosine triphosphate
,8593479,biological half-life,"After intravenous bolus injection, Ap4A in plasma declined rapidly and the rate of elimination was dose-dependent: the biological half-life was about 3s at the dose of 1 mg/kg and was longer at 3 mg/kg.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),s,3,90736,DB00171,Adenosine triphosphate
,25614114,inhibitory activities (IC50),The observed ATPase inhibitory activities (IC50) of these compounds range between 0.36 and 5.45μM.,"Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),μM,0.36 and 5.45,91578,DB00171,Adenosine triphosphate
>,25614114,CC50,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),[μg] / [ml],300,91579,DB00171,Adenosine triphosphate
,25614114,IC50,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),μM,0.51,91580,DB00171,Adenosine triphosphate
>,25614114,IC50,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),μM,100,91581,DB00171,Adenosine triphosphate
>,25614114,selectivity,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),,200,91582,DB00171,Adenosine triphosphate
,25614114,volume of distribution (Vss,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),[l] / [kg],0.41,91583,DB00171,Adenosine triphosphate
,25614114,clearance,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),[l] / [h·kg],0.06,91584,DB00171,Adenosine triphosphate
,25614114,half-life,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),h,4.2,91585,DB00171,Adenosine triphosphate
,25614114,absolute bioavailability,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),%,1.72,91586,DB00171,Adenosine triphosphate
,15229462,plasma levels,"The ABCG2 421C>A genotype significantly affected the pharmacokinetics of diflomotecan; in 5 patients heterozygous for this allele, plasma levels after intravenous drug administration were 299% (P =.015) of those in 15 patients with wild-type alleles, at mean values of 138 ng x h/mL x mg(-1) (95% confidence interval, 11.3-264 ng x h/mL x mg(-1)) versus 46.1 ng x h/mL x mg(-1) (95% confidence interval, 25.6-66.7 ng x h/mL x mg(-1)), respectively.",Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229462/),[h·ml·ng] / [mg],46.1,92257,DB00171,Adenosine triphosphate
,31517281,tmax,"In vivo tmax of the IM administered poloxamer in situ forming gels was about 6 h and a short-term sustained drug release was observed in vivo in rats up to 24 h after dosing, similar to a solution of bedaquiline fumarate salt in polyethylene glycol (PEG400)/water.",In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31517281/),h,6,92697,DB00171,Adenosine triphosphate
,20386016,t(max),"RO5068760 was absorbed with a t(max), of 2 hours.","The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386016/),h,2,97686,DB00171,Adenosine triphosphate
,20386016,terminal elimination t(1/2),Disposition appeared to be biphasic with a terminal elimination t(1/2) of 5 to 9 hours.,"The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386016/),h,5 to 9,97687,DB00171,Adenosine triphosphate
,33822617,clearance,"The rat pharmacokinetic profile is favorable with high oral bioavailability, modest clearance (0.79 L/(h kg)), and good CNS permeability.",Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822617/),[l] / [h·kg],0.79,99836,DB00171,Adenosine triphosphate
,33835812,A2,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104512,DB00171,Adenosine triphosphate
,33835812,EC50,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104513,DB00171,Adenosine triphosphate
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,9,112236,DB00171,Adenosine triphosphate
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,4,112237,DB00171,Adenosine triphosphate
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,2.3,116519,DB00171,Adenosine triphosphate
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,6.4,116520,DB00171,Adenosine triphosphate
,30745177,time to sputum culture conversion,The time to sputum culture conversion was 14-15 days.,"Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),d,14-15,116715,DB00171,Adenosine triphosphate
,30745177,AUC24h,"Plasma bedaquiline Cmax was achieved within 4-6 h of bedaquiline administration and AUC24h ranged from 50,637 to 107,300 ng*h/mL (5 patients) at week 2 and were 58,513 and 77,148 ng *h/mL (2 patients) at week 24.","Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),[h·ng] / [ml],50,116716,DB00171,Adenosine triphosphate
,30745177,AUC24h,"Plasma bedaquiline Cmax was achieved within 4-6 h of bedaquiline administration and AUC24h ranged from 50,637 to 107,300 ng*h/mL (5 patients) at week 2 and were 58,513 and 77,148 ng *h/mL (2 patients) at week 24.","Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),[h·ng] / [ml],"58,513",116717,DB00171,Adenosine triphosphate
,30745177,AUC24h,"Plasma bedaquiline Cmax was achieved within 4-6 h of bedaquiline administration and AUC24h ranged from 50,637 to 107,300 ng*h/mL (5 patients) at week 2 and were 58,513 and 77,148 ng *h/mL (2 patients) at week 24.","Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),[h·ng] / [ml],"77,148",116718,DB00171,Adenosine triphosphate
,11451028,IC50,"In a cell line presenting an overexpressed amount of the human transporter, the enzyme exhibited a 40 microM IC50 for inhibition by bergamottin.",Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451028/),μM,40,117814,DB00171,Adenosine triphosphate
,11451028,Km,"Additionally, using the ATP-hydrolysis assay, we showed that bergamottin increases P-gp-mediated ATP hydrolysis by approximately 2.3 fold with a Km of 8 microM.",Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451028/),μM,8,117815,DB00171,Adenosine triphosphate
,30215770,C1,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],8.3,128963,DB00171,Adenosine triphosphate
,30215770,C2,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],7.2,128964,DB00171,Adenosine triphosphate
,30215770,C12,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.0,128965,DB00171,Adenosine triphosphate
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.3,128966,DB00171,Adenosine triphosphate
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],4.3,128967,DB00171,Adenosine triphosphate
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.9,128968,DB00171,Adenosine triphosphate
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.4,128969,DB00171,Adenosine triphosphate
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.8,128970,DB00171,Adenosine triphosphate
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.7,128971,DB00171,Adenosine triphosphate
,20197013,Renal clearance,Renal clearance decreased by a factor 0.88 from 111 to 97.3 ml/min while digoxin half-life increased from 37.0 to 45.3 h.,Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197013/),[ml] / [min],111,132189,DB00171,Adenosine triphosphate
,20197013,half-life,Renal clearance decreased by a factor 0.88 from 111 to 97.3 ml/min while digoxin half-life increased from 37.0 to 45.3 h.,Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197013/),h,37.,132190,DB00171,Adenosine triphosphate
,20197013,half-life,Renal clearance decreased by a factor 0.88 from 111 to 97.3 ml/min while digoxin half-life increased from 37.0 to 45.3 h.,Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197013/),h,45,132191,DB00171,Adenosine triphosphate
less,1551186,half-life,Thus a single dose of ATP-MgCl2 has a half-life of less than 40 sec as ATP.,Clearance and maintenance of blood nucleotide levels with adenosine triphosphate-magnesium chloride injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551186/),s,40,132296,DB00171,Adenosine triphosphate
,24070396,clearance index,"The normalized transfer of pravastatin (clearance index) to antipyrine in the fetal-to-maternal direction (0.48 ± 0.07) was higher than its transfer in the maternal-to-fetal direction (0.36 ± 0.07, P < .01).",Transplacental transfer and distribution of pravastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24070396/),,0.,132994,DB00171,Adenosine triphosphate
,34221871,t 1/2,"In our in vitro assessments, RDV exhibited prohibitively low stability in human liver microsomes (HLMs, t 1/2 = ∼1 min), with the primary CYP-mediated metabolism being the mono-oxidation likely on the phosphoramidate moiety.",Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34221871/),min,∼1,134202,DB00171,Adenosine triphosphate
,34221871,oral bioavailability,"In further in vivo studies in CD-1 mice, GS-441524 displayed a favorable oral bioavailability of 57%.",Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34221871/),%,57,134203,DB00171,Adenosine triphosphate
,15855513,t(1/2) of elimination,"In the case of TFV-DP, this t(1/2) of elimination was roughly estimated to be 180 h (7.5 days).",Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855513/),h,180,152630,DB00171,Adenosine triphosphate
,15855513,t(1/2) of elimination,"In the case of TFV-DP, this t(1/2) of elimination was roughly estimated to be 180 h (7.5 days).",Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855513/),d,7.5,152631,DB00171,Adenosine triphosphate
,27517813,bioavailability,Its bioavailability at an oral dose of 2 mg/kg was 15%.,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517813/),%,15,157381,DB00171,Adenosine triphosphate
,29257872,AUCbrain,"SC insulin (2.4 IU) achieved therapeutically relevant concentrations in the brain (AUCbrain = 2537 h·μIU/mL) but dramatically increased plasma insulin (AUCplasma = 520 351 h·*μIU/mL), resulting in severe hypoglycemia and in some cases death.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],2537,157792,DB00171,Adenosine triphosphate
,29257872,AUCplasma,"SC insulin (2.4 IU) achieved therapeutically relevant concentrations in the brain (AUCbrain = 2537 h·μIU/mL) but dramatically increased plasma insulin (AUCplasma = 520 351 h·*μIU/mL), resulting in severe hypoglycemia and in some cases death.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],520 351,157793,DB00171,Adenosine triphosphate
,29257872,AUCbrain,"IN administration of the same dose resulted in similar insulin levels in the brain (AUCbrain = 3442 h·μIU/mL) but substantially lower plasma concentrations (AUCplasma = 354 h·μIU/mL), amounting to a ∼ 2000-fold increase in the AUCbrain:plasma ratio relative to SC.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],3442,157794,DB00171,Adenosine triphosphate
,29257872,AUCplasma,"IN administration of the same dose resulted in similar insulin levels in the brain (AUCbrain = 3442 h·μIU/mL) but substantially lower plasma concentrations (AUCplasma = 354 h·μIU/mL), amounting to a ∼ 2000-fold increase in the AUCbrain:plasma ratio relative to SC.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],354,157795,DB00171,Adenosine triphosphate
,27138785,concentration (C 0),Dose simulations show that a daily tacrolimus dose of 0.2 mg/kg generates a pre-dose concentration (C 0) ranging from 5 to 10 µg/L depending on the weight and CYP3A5 polymorphism.,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[μg] / [l],5 to 10,160046,DB00171,Adenosine triphosphate
,27138785,area under the plasma concentration-time curve (AUC),The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[h·μg] / [l],97,160047,DB00171,Adenosine triphosphate
,27138785,C 0,The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[μg] / [l],4-8,160048,DB00171,Adenosine triphosphate
,27138785,C 0,The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[h·μg] / [l],97,160049,DB00171,Adenosine triphosphate
,9667246,MTD,The MTD of HU given as a 24-hour infusion was 27 g/m2.,Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9667246/),[g] / [m2],27,160656,DB00171,Adenosine triphosphate
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,12.0,166574,DB00171,Adenosine triphosphate
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,3.5,166575,DB00171,Adenosine triphosphate
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,4558,178766,DB00171,Adenosine triphosphate
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,"136,572",178767,DB00171,Adenosine triphosphate
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,2896,178768,DB00171,Adenosine triphosphate
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,"35,819",178769,DB00171,Adenosine triphosphate
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1740,178770,DB00171,Adenosine triphosphate
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1253,178771,DB00171,Adenosine triphosphate
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],127,178772,DB00171,Adenosine triphosphate
,25271258,brain-to-plasma ratio,"In this study, we characterized JNJ-42253432 [2-methyl-N-([1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide] as a centrally permeable (brain-to-plasma ratio of 1), high-affinity P2X7 antagonist with desirable pharmacokinetic and pharmacodynamic properties for in vivo testing in rodents.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,1,200086,DB00171,Adenosine triphosphate
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,9.1,200087,DB00171,Adenosine triphosphate
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,7.9,200088,DB00171,Adenosine triphosphate
,25271258,ED50,"When dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED50 of 0.3 mg/kg, corresponding to a mean plasma concentration of 42 ng/ml.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],0.3,200089,DB00171,Adenosine triphosphate
,25271258,ED50,"At higher doses/exposure, JNJ-42253432 also increased serotonin levels in the rat brain, which is due to antagonism of the serotonin transporter (SERT) resulting in an ED50 of 10 mg/kg for SERT occupancy.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],10,200090,DB00171,Adenosine triphosphate
,20237073,K(i),PF-3644022 is a potent freely reversible ATP-competitive compound that inhibits MK2 activity (K(i) = 3 nM) with good selectivity when profiled against 200 human kinases.,A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),nM,3,207882,DB00171,Adenosine triphosphate
,20237073,IC(50),"In the human U937 monocytic cell line or peripheral blood mononuclear cells, PF-3644022 potently inhibits TNFalpha production with similar activity (IC(50) = 160 nM).",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),nM,160,207883,DB00171,Adenosine triphosphate
,20237073,IC(50),"PF-3644022 blocks TNFalpha and IL-6 production in LPS-stimulated human whole blood with IC(50) values of 1.6 and 10.3 microM, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),μM,1.6,207884,DB00171,Adenosine triphosphate
,20237073,IC(50),"PF-3644022 blocks TNFalpha and IL-6 production in LPS-stimulated human whole blood with IC(50) values of 1.6 and 10.3 microM, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),μM,10.3,207885,DB00171,Adenosine triphosphate
,20237073,ED(50),"Dose-dependent inhibition of TNFalpha production in the acute model and inhibition of paw swelling in the chronic model is observed with ED(50) values of 6.9 and 20 mg/kg, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),[mg] / [kg],6.9,207886,DB00171,Adenosine triphosphate
,20237073,ED(50),"Dose-dependent inhibition of TNFalpha production in the acute model and inhibition of paw swelling in the chronic model is observed with ED(50) values of 6.9 and 20 mg/kg, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),[mg] / [kg],20,207887,DB00171,Adenosine triphosphate
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],7.7,213912,DB00171,Adenosine triphosphate
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],8.8,213913,DB00171,Adenosine triphosphate
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],3.2,213914,DB00171,Adenosine triphosphate
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],4.0,213915,DB00171,Adenosine triphosphate
,10561275,C(max),"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],30,213916,DB00171,Adenosine triphosphate
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],55,213917,DB00171,Adenosine triphosphate
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],106,213918,DB00171,Adenosine triphosphate
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],7.78,214333,DB00171,Adenosine triphosphate
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],10.6,214334,DB00171,Adenosine triphosphate
,7018678,alpha-phase half-life,"The alpha-phase half-life of LV was about 15 mins, but LV was readily detectable by the assay for 3-4 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),min,15,218709,DB00171,Adenosine triphosphate
,7018678,apparent half-life,"The level of mTHFA increased for at least 60 mins, being equimolar with LV by 30 mins, and then decreased slowly with an apparent half-life of 2-3 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),h,2-3,218710,DB00171,Adenosine triphosphate
,29787262,oral bioavailability,"What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.",Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29787262/),%,72,231871,DB00171,Adenosine triphosphate
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],5.81,232760,DB00171,Adenosine triphosphate
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],11.30,232761,DB00171,Adenosine triphosphate
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,15.2,232762,DB00171,Adenosine triphosphate
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,43.4,232763,DB00171,Adenosine triphosphate
,34341510,IC50,"Among 6 known K2P channel modulators tested (DCPIB, quinine, fluoxetine, ML365, ML335, and TKDC), ML365 was the most potent TWIK2 channel blocker with an IC50 value of 4.07 ± 1.5 μM.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),μM,4.07,233069,DB00171,Adenosine triphosphate
,34341510,F,"In a preliminary pharmacokinetic study conducted in rats, ML365 showed good absolute oral bioavailability with F value of 22.49%.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),%,22.49,233070,DB00171,Adenosine triphosphate
,10853877,ATP concentration,"Baseline ATP concentration in erythrocytes was 1,554 +/- 51 micromol l(-1).",Pharmacokinetics of intravenous ATP in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853877/),[μM] / [l],"1,554",233610,DB00171,Adenosine triphosphate
,10853877,half-time for disappearance,"The mean half-time for disappearance of ATP from erythrocytes, measured in five patients, was 5.9 +/- 0.5 h.",Pharmacokinetics of intravenous ATP in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853877/),h,5.9,233611,DB00171,Adenosine triphosphate
,24023367,Km,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),μM,21,236646,DB00171,Adenosine triphosphate
,24023367,Vmax,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),[pM] / [milligram·min],1140,236647,DB00171,Adenosine triphosphate
,23361621,MTD,The MTD is 40 mg BID continuously.,"A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23361621/),mg,40,242438,DB00171,Adenosine triphosphate
,23361621,CA19-9,"Patients with prostate and pancreatic cancer also had significant biomarker decreases (PSA, 205 ng/mL to 39 ng/mL; CA19-9, 38,838 U/mL to 267 U/mL).","A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23361621/),[u] / [ml],"38,838",242439,DB00171,Adenosine triphosphate
,23361621,CA19-9,"Patients with prostate and pancreatic cancer also had significant biomarker decreases (PSA, 205 ng/mL to 39 ng/mL; CA19-9, 38,838 U/mL to 267 U/mL).","A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23361621/),[u] / [ml],267,242440,DB00171,Adenosine triphosphate
,12089223,area under the plasma concentration-time curve (AUC),"After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 +/- 9.6 microg.h/L without GF120918 to 78.7 +/- 20.6 microg.h/L when GF120918 was coadministered (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[h·μg] / [l],32.4,242480,DB00171,Adenosine triphosphate
,12089223,area under the plasma concentration-time curve (AUC),"After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 +/- 9.6 microg.h/L without GF120918 to 78.7 +/- 20.6 microg.h/L when GF120918 was coadministered (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[h·μg] / [l],78.7,242481,DB00171,Adenosine triphosphate
,12089223,maximum plasma concentration,The mean maximum plasma concentration of total topotecan increased from 4.1 +/- 1.5 microg/L without GF120918 to 11.5 +/- 2.4 microg/L with GF120918 (P =.008).,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[μg] / [l],4.1,242482,DB00171,Adenosine triphosphate
,12089223,maximum plasma concentration,The mean maximum plasma concentration of total topotecan increased from 4.1 +/- 1.5 microg/L without GF120918 to 11.5 +/- 2.4 microg/L with GF120918 (P =.008).,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[μg] / [l],11.5,242483,DB00171,Adenosine triphosphate
,12089223,apparent bioavailability,"The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,40.0,242484,DB00171,Adenosine triphosphate
,12089223,apparent bioavailability,"The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,97.1,242485,DB00171,Adenosine triphosphate
,12089223,apparent bioavailability,Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,17,242486,DB00171,Adenosine triphosphate
,12089223,apparent bioavailability,Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,11,242487,DB00171,Adenosine triphosphate
,12089223,apparent oral bioavailability,The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,40.0,242488,DB00171,Adenosine triphosphate
,12089223,apparent oral bioavailability,The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,97.1,242489,DB00171,Adenosine triphosphate
,25150000,fm,"Following iv PCr, Cr appeared in plasma as early as 1.0 min postdose with a longer t1/2 than PCr and had a fm of 72%.",Pharmacokinetics of phosphocreatine and its active metabolite creatine in the mouse plasma and myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150000/),%,72,245320,DB00171,Adenosine triphosphate
,30260294,plasma effective concentration (EC)50,Target plasma concentrations were based on estimated plasma effective concentration (EC)50 (105 ng/mL) and EC90 (900 ng/mL) values for central nervous system P2X7 receptor binding.,"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],105,247751,DB00171,Adenosine triphosphate
,30260294,EC90,Target plasma concentrations were based on estimated plasma effective concentration (EC)50 (105 ng/mL) and EC90 (900 ng/mL) values for central nervous system P2X7 receptor binding.,"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],900,247752,DB00171,Adenosine triphosphate
,30260294,Cmax,"The highest Cmax,plasma reached (600 mg, fed) was 1475±163 ng/mL.","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],1475,247753,DB00171,Adenosine triphosphate
,30260294,unbound Cmax,"JNJ-54175446 Cmax in cerebrospinal fluid, a proxy for brain penetration, was seven times lower than in total plasma; unbound Cmax,plasma and Cmax,CSF were comparable (88.3±35.7 vs 114±39 ng/mL).","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],88.3,247754,DB00171,Adenosine triphosphate
,30260294,Cmax,"JNJ-54175446 Cmax in cerebrospinal fluid, a proxy for brain penetration, was seven times lower than in total plasma; unbound Cmax,plasma and Cmax,CSF were comparable (88.3±35.7 vs 114±39 ng/mL).","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],88.3,247755,DB00171,Adenosine triphosphate
,30260294,Cmax,"JNJ-54175446 Cmax in cerebrospinal fluid, a proxy for brain penetration, was seven times lower than in total plasma; unbound Cmax,plasma and Cmax,CSF were comparable (88.3±35.7 vs 114±39 ng/mL).","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],114,247756,DB00171,Adenosine triphosphate
,30260294,inhibitory concentration (IC)50,JNJ-54175446 inhibited lipopolysaccharide/3'-O-(4-benzoylbenzoyl)-ATP-induced interleukin-1β release from peripheral blood in a dose-dependent manner (inhibitory concentration (IC)50:82 ng/mL; 95% confidence interval: 48-94).,"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],82,247757,DB00171,Adenosine triphosphate
,27785737,plasma half-life,Entospletinib displayed a median plasma half-life of 9-15 h; entospletinib exposures reached a plateau at ≥600 mg twice daily (likely due to solubility-limited absorption) and provided >90% CD63 inhibition at peak concentrations and >60% inhibition at trough concentrations (corresponding pSYK inhibition of >70 and >50%).,"Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27785737/),h,9-15,258854,DB00171,Adenosine triphosphate
,24440085,MTD,The MTD was determined to be 75 mg BID or 100mg QD.,"A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440085/),,75,270020,DB00171,Adenosine triphosphate
